Regimmune Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Tokyo Japan (2006)

Organization Overview

First Clinical Trial
2011
NCT01379209
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Regimmune Corporation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Graft vs Host Disease (Phase 2)

Hodgkin Disease (Phase 1)

Leukemia (Phase 1)

Leukemia, Lymphoid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Leukemia, Myelomonocytic, Chronic (Phase 1)

Leukemia, Myelomonocytic, Juvenile (Phase 1)

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Myeloproliferative Disorders (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Preleukemia (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 7